Table 1 Characteristics of the included articles (n = 85)
Characteristic | |
|---|---|
Author-level variables | |
Affiliation of the corresponding authora | |
  European institute, no. (%) | 49 (57.6) |
   Finland, no. (%) | 6 (7.1) |
   Germany, no. (%) | 10 (11.8) |
   Spain, no. (%) | 3 (3.5) |
   Sweden, no. (%) | 4 (4.7) |
   Switzerland, no. (%) | 3 (3.5) |
   The Netherlands, no. (%) | 4 (4.7) |
   UK, no. (%) | 12 (14.1) |
  Non-European institute, no. (%) | 36 (42.4) |
   Australia, no. (%) | 18 (21.2) |
   New Zealand, no. (%) | 4 (4.7) |
   USA, no. (%) | 9 (10.6) |
Study-level variables | |
 Setting | |
  Community, no. (%) | 69 (81.2) |
  Other, no. (%) | 16 (18.8) |
   Assisted living, no. (%) | 1 (1.2) |
   Hospital, no. (%) | 5 (5.9) |
   Long-term care/nursing home, no. (%) | 6 (7.1) |
   Combined, no. (%) | 4 (4.7) |
 Number of trial centres | |
  Multiple, no. (%) | 53 (62.4) |
  Single, no. (%) | 19 (22.4) |
  Not reported, no. (%) | 13 (15.3) |
 Number of trial arms | |
  Two, no. (%) | 67 (78.8) |
  Three or more, no. (%) | 18 (21.2) |
 Funding source | |
  Industry, no. (%) | 3 (3.5) |
  Non-industry, no. (%) | 63 (74.1) |
  Combined, no. (%) | 12 (14.1) |
  None, no. (%) | 3 (3.5) |
  Not reported or unclear, no. (%) | 4 (4.7) |
 Intervention type | |
  Exercise, no. (%) | 26 (30.6) |
  Multi-component/factorial, no. (%) | 38 (44.7) |
  Other, no. (%) | 21 (24.7) |
 Mean age of trial participants at baseline | |
  Years, mean (SD) | 76.8 (5.3) |
  Years, minimum | 62 |
  Years, maximum | 88 |
 Female participants at baseline | |
  %, mean (SD) | 68.1 (17.8) |
  %, minimum | 0 |
  %, maximum | 100 |
 Whether population of interest living with disease at baseline | |
  No, no. (%) | 61 (71.8) |
  Yes, no. (%) | 24 (28.2) |
   Dementia or cognitive impairment, no. (%) | 6 (7.0) |
   Parkinson’s disease and/or stroke, no. (%) | 5 (5.9) |
  Other, no. (%) | 13 (15.3) |
 Fall risk of trial participants at baseline | |
  At high riskb, no. (%) | 49 (57.6) |
  At risk, no. (%) | 36 (42.4) |
 Sample size at baseline | |
  Mean (SD) | 837.2 (2029.3) |
  Minimum | 23 |
  Maximum | 12,483 |
 Length of follow-up of primary outcome | |
  Less than 12 months, no. (%) | 32 (37.6) |
  12 or more months, no. (%) | 52 (61.2) |
  Not reported, no. (%) | 1 (1.2) |
Manuscript-level variables | |
 Year of publication | |
  2007–2011, no. (%) | 22 (25.9) |
  2012–2016, no. (%) | 30 (35.3) |
  2017–2021, no. (%) | 33 (38.5) |
 Journal type | |
  Specialist, no. (%) | 62 (72.9) |
  General, no. (%) | 23 (27.1) |
 Citation of ProFaNE core outcome set | |
  Introduction, no. (%) | 12 (14.1) |
  Methods, no. (%) | 72 (84.7) |
  Results, no. (%) | 1 (1.2) |
  Discussion, no. (%) | 17 (20.0) |